Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world. Therefore, new therapeutic options are urgently needed to improve the survival of PDAC patients. Protein kinase G (PKG) conducts the interlude of cGMP signaling which is important for healthy as well as for cancer cells. DT3 is a specific inhibitor of PKG, and it has been shown to possess an anti-tumor cytotoxic activity in vitro. The main aim of this work was to investigate anti-tumor effects of DT3 upon PDAC in vivo.
Expression of PKG was assessed with real-time PCR analysis in the normal and tumor pancreatic cells. In vitro cell viability, proliferation, apoptosis, necrosis, migration, and invasion of the murine PDAC cell line Panc02 were assessed after DT3 treatment. In vivo anti-tumor effects of DT3 were investigated in the murine Panc02 orthotopic model of PDAC. Western blot analysis was used to determine the phosphorylation state of the proteins of interest.
Functional PKGI is preferentially expressed in PDAC cells. DT3 was capable to reduce viability, proliferation, and migration of murine PDAC cells in vitro. At the same time, DT3 treatment did not change the viability of normal epithelial cells of murine liver. In vivo, DT3 treatment reduced the tumor volume and metastases in PDAC-bearing mice, but it was ineffective to prolong the survival of the tumor-bearing animals. In addition, DT3 treatment decreased phosphorylation of GSK-3, P38, and CREB in murine PDAC.
Inhibition of PKG could be a potential therapeutic strategy for PDAC treatment which should be carefully validated in future pre-clinical studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- GC:
-
Guanylyl cyclase
- PDAC:
-
Pancreatic ductal adenocarcinoma
- PKG:
-
Protein kinase G
References
Bazhin AV, Schadendorf D, Owen RW, Zernii EY, Philippov PP, Eichmüller SB (2008) Visible light modulates the expression of cancer-retina antigens. Mol Cancer Res 6:110–118
Bazhin AV, Bayry J, Umansky V, Werner J, Karakhanova S (2013) Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Oncoimmunology 2:e25736. doi:10.4161/onci.25736
Bazhin AV, Shevchenko I, Umansky V, Werner J, Karakhanova S (2014) Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunol Immunother 63:59–65. doi:10.1007/s00262-013-1485-8
Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP, Boffetta P (2012) Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 51:3–13. doi:10.1002/mc.20785
Bryan NS, Bian K, Murad F (2009) Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci 14:1–18
Cary SP, Winger JA, Derbyshire ER, Marletta MA (2006) Nitric oxide signaling: no longer simply on or off. Trends Biochem Sci 31:231–239. doi:10.1016/j.tibs.2006.02.003
Conroy T et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. doi:10.1056/NEJMoa1011923
Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R, Tegge WJ (2000) Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc Natl Acad Sci U S A 97:14772–14777. doi:10.1073/pnas.97.26.14772
Fraser M, Chan SL, Chan SS, Fiscus RR, Tsang BK (2006) Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25:2203–2212. doi:10.1038/sj.onc.1209251
Gambaryan S et al. (2012) The oligopeptide DT-2 is a specific PKG I inhibitor only in vitro, not in living cells. Br J Pharmacol 167:826–838. doi:10.1111/j.1476-5381.2012.02044.x
Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148:362–375. doi:10.1016/j.cell.2011.11.060
Karakhanova S, Golovastova M, Philippov PP, Werner J, Bazhin AV (2014a) Interlude of cGMP and cGMP/protein kinase G type 1 in pancreatic adenocarcinoma cells. Pancreas 43:784–794. doi:10.1097/MPA.0000000000000104
Karakhanova S et al. (2014b) Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. Int J Mol Sci 15:4104–4125. doi:10.3390/ijms15034104
Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049–1057. doi:10.1016/S0140-6736(04)15841-8
Rosty C, Goggins M (2002) Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 16:37–52
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108
Shevchenko I et al. (2013) Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 133:98–107. doi:10.1002/ijc.27990
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29. doi:10.3322/caac.20138
Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455–465
Zhu Y, Karakhanova, S., Huang, X., Deng, S., Werner, J., Bazhin AV. (2014) Influence of interferon-<alpha> on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Exp Cell Res 323
Acknowledgments
We are grateful to Mr. M. Herbst and Ms. Tina Maxelon for their excellent technical assistance. This work was supported by grants from Wilhelm Sander-Stiftung (2011.036.1) to AVB and JW, and from Russian Foundation for Basic Research (#15–04–05171) to PPPh.
Author information
Authors and Affiliations
Corresponding author
Additional information
Sabine Soltek and Svetlana Karakhanova equally contributed to this study.
Rights and permissions
About this article
Cite this article
Soltek, S., Karakhanova, S., Golovastova, M. et al. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. Naunyn-Schmiedeberg's Arch Pharmacol 388, 1121–1128 (2015). https://doi.org/10.1007/s00210-015-1147-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-015-1147-9